



Around the world: access to therapy

Introduction - Massimo Colombo (Italy)

Western Countries

Chair: Massimo Colombo (Italy)

Speakers: Maria Buti (Spain), Antonio Craxi (Italy), Graham Foster (UK), Michael Fried (USA), Victor de Ledinghen (France), Stefan Zeuzem (Germany)

Other Countries

Chair: Michael Fried (USA)

Speakers: Mustapha Benazzouz (Morocco), Robert Flisiak (Poland), Jinlin Hou (UK), Vasily Isakov (Russia), Adriana Popescu (Romania), Raymundo Parana Filho (Brazil)

Current situation of hepatitis C in Spain

- ✓ Prevalence of HCV-RNA¹ 0.8% (0,3-1,8%)
- ✓ Total number of viremic patients¹ 386.000 (159.000–557.000)
- ✓ Mortality² approx 4.000 cases per year
- ✓ Number of liver transplantation³ 24.905 (45% related to HCV=11.207)
- ✓ Total number of patients treated so far approx 120.000
- ✓ Total number of patients treated per year² 30.000

1.- Polaris Observatory HCV: [Lance.gastrohep](#), 2016

2.www.msssi.gob.es/.../hepatitisC/PlanEstrategicoHEPATITISC. 3.-www.ont.es

Ressources currently available in Spain

- ✓ Current resources provided by Health Authorities
 - 1 billion euros (Plan National Against Hepatitis C 2015-2017)
- ✓ Drugs available
 - ALL except Sofosbuvir/Velpatasvir
- ✓ Plans for screening
 - High Risk groups
 - Two epidemiological studies on-going
- ✓ Plans for access to treatment
 - National Plan : Access to treatment \geq F2, high transmitters and extrahepatic manifestations independently of fibrosis degree

Actions planned in Spain

- ✓ To improve screening/To facilitate access to treatment
 - National Plan under discussion therapy for all HCV infected subjects
- ✓ Future drugs available in 2017
 - SOF/VEL
 - Glecaprevir/pibrentasvir
- ✓ Major future actions planned against hepatitis C
 - Update the National Plan
 - AEEH Institucional Symposium on HCV
 - Alliance group